Finally, imatinib, a tyrosine kinase inhibitor, improved β-cell glucose and insulin sensitivity in R-T1D but surprisingly had no effects on proinflammatory immune responses [61,62]. The gene discussed is INS; the disease is type 1 diabetes mellitus.